# OnCo record esphall (trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/trials/esphall/>
  a schema:MedicalTrial ;
  onco:kind "trial" ;
  schema:identifier "esphall", "NCT00287105" ;
  schema:name "EsPhALL (EsPhALL2004 and EsPhALL2010)"@en ;
  schema:alternateName "EsPhALL"@en, "ESPHALL"@en, "EsPhALL2004"@en, "EsPhALL2010"@en ;
  schema:description "EsPhALL is the European intergroup study that brought the leukaemia pill imatinib into treatment for children with Philadelphia-positive acute lymphoblastic leukaemia; the first version gave it in short bursts after induction and the second gave it continuously, and together they set the chemotherapy backbone that the standard of care still uses."@en ;
  schema:url <https://onco.cc/trials/esphall/> ;
  schema:dateModified "2026-09-22"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/study/NCT00287105> ;
  onco:status "completed" ;
  onco:tag "soc-trials" ;
  onco:phase "2" ;
  onco:cancers <https://onco.cc/cancers/all-paediatric-ph-positive/>, <https://onco.cc/cancers/all-leukemia/>, <https://onco.cc/cancers/leukaemia/> ;
  onco:technologies <https://onco.cc/technologies/kinase-inhibitors/>, <https://onco.cc/technologies/cytotoxic-chemotherapy/>, <https://onco.cc/technologies/allogeneic-hsct/> ;
  onco:drugs <https://onco.cc/drugs/imatinib/> ;
  onco:companies <https://onco.cc/companies/novartis/> ;
  onco:keyPapers <https://onco.cc/key-papers/paper-esphall-imatinib-biondi-lancet-oncol-2012/>, <https://onco.cc/key-papers/paper-esphall2010-continuous-imatinib-biondi-lancet-haematol-2018/> .